Sekisui To Send Staff To Xenotech And Strengthen Contract Pharmacokinetics Study Business
This article was originally published in PharmAsia News
Executive Summary
Sekisui Medical plans to strengthen its contract pharmacokinetics studies business and new product development in the U.S. in 2009. The company will send management and staff to Kansas-based Xenotech, a U.S. in vitro drug metabolism and drug-drug interaction studies provider acquired by Sekisui last July. The company also aims to expand the U.S. and European markets for its testing drugs by establishing its own sales networks and increasing staff in the U.S. and German offices. Sekisui aims to increase overseas sales from its current 17 percent to 20 percent in 2009. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.